Anti-aging Elevian debuts with $5.5M seed funding

Regenerative medicine company Elevian Inc. (Allston, Mass.) launched on Sept. 6 with $5.5 million in seed funding from Bold Capital, WTI, Stanford StartX fund, Longevity Fund, Kizoo Ventures, Thynk Capital and additional undisclosed investors.

Elevian aims to develop therapeutics that increase levels of growth differentiation factor 11 (GDF11) to treat diseases associated with aging, such as coronary artery disease, Alzheimer's disease, Type II diabetes and sarcopenia...